Open AccessEffect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy
Author(s) -
Marcel Levi,
JeanLouis Vincent,
Kosuke Tanaka,
Amanda Radford,
Toshihiko Kayanoki,
David Fineberg,
Debra Hoppensteadt,
Jawed Fareed
Publication year - 2020
Publication title -
critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.002
H-Index - 271
eISSN - 1530-0293
pISSN - 0090-3493
DOI - 10.1097/ccm.0000000000004426
Subject(s) - thrombomodulin , medicine , coagulopathy , antithrombin , sepsis , prothrombin time , gastroenterology , disseminated intravascular coagulation , placebo , anticoagulant , immunology , thrombin , platelet , pathology , heparin , alternative medicine
To assess the effects of recombinant human soluble thrombomodulin treatment on 28-day all-cause mortality in subgroups categorized by baseline coagulation biomarker levels (prothrombin fragment 1.2, thrombin-antithrombin complex, D-dimer) in patients with sepsis-associated coagulopathy in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial (SCARLET) (NCT01598831).